Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact
Clinical Trials in Italy / NCT07808047
Active, not recruiting Observational

Dynamic Pupil Variations and the Efficacy of Peripheral Defocus Spectacle Lenses in Slowing Myopia Progression

NCT07808047 · tracked via the Priya Life Science Italy tracker
Sponsor
Bambino Gesù Hospital and Research Institute
Phase
Observational
Started
2024-08-01
Last updated
2026-09-08

Condition(s) studied

Myopia Progressing

Investigational drug(s) / intervention(s)

perifheral defocus spectacle lensesperipheral defocus spectacle lens

perifheral defocus spectacle lenses: dynamic pupillometry measurement

peripheral defocus spectacle lens: 24 month follow up

Study summary

to evaluate the correlation between dynamic pupil variations and the efficacy of spectacle lenses in myopia progression control

Eligibility

Sex
ALL
Min age
6 Years
Max age
18 Years
Healthy volunteers
No
Inclusion Criteria: progressive myopia Exclusion Criteria: suspected genetic syndromes all systemic or eye diseases

Primary outcome measure(s)

Trial sites (1)

FacilityCityRegionStatus
Luca Buzzonetti Roma Italy

More Bambino Gesù Hospital and Research Institute trials in Italy

CD19-CAR_Lenti T Cells in Pediatric Patients Affected by Relapsed/Refractory CD19+ ALL and DLBCL or PML Active, not recruiting
Group CBT in Adolescents With Fragile X Syndrome and in Adolescents With Autism Spectrum Disorder Recruiting
Framework for Optimizing, Refining, and Unifying Management of HSCT in Pediatric ALL Starting soon
Reprogramming Energy Homeostasis in Overweight Individuals Via Exercise, Cognitive, and Social Training Recruiting
GD2-CAR T Cells for Pediatric Brain Tumours Recruiting
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT07808047 on ClinicalTrials.gov ↗ ← All trials in Italy